Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income (2019 - 2025)

Keros Therapeutics filings provide 7 years of Non Operating Income readings, the most recent being $273000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 101.59% to $273000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 197.35% increase, with the full-year FY2025 number at -$539000.0, up 43.5% from a year prior.
  • Non Operating Income hit $273000.0 in Q4 2025 for Keros Therapeutics, up from -$253000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $9.3 million in Q4 2022 to a low of -$17.2 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was -$62000.0 (2021), compared with a mean of $269050.0.
  • Biggest five-year swings in Non Operating Income: surged 12529.33% in 2022 and later tumbled 280.23% in 2023.
  • Keros Therapeutics' Non Operating Income stood at -$75000.0 in 2021, then surged by 12529.33% to $9.3 million in 2022, then plummeted by 217.39% to -$10.9 million in 2023, then crashed by 57.23% to -$17.2 million in 2024, then surged by 101.59% to $273000.0 in 2025.
  • The last three reported values for Non Operating Income were $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and $6.9 million (Q2 2025) per Business Quant data.